Comparison
Retatrutide vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
2381089-83-2
62304-98-7
Molecular weight
4731.6 g/mol
3108.32 g/mol
Half-life
144 h
2 h
Sequence
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSAc-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
4
2
Effects recorded
4
3
Open conflicts
0
1
Documented adverse events
2
1